CLEC12A and acute myeloid leukemia: Upon analysis of 52 de novo or relapsed AML samples, we confirmed that CLL-1 was expressed on the cell surface of the majority of AML blasts (78.8%), clearly indicating that the CLL-1 could be used to be the routine FCM in AML.